SCHEDULES
SCHEDULE 2Transitionals and savings
Part 15Research and development
Qualifying expenditure on relevant payments to subjects of clinical trials
124
1
In relation to expenditure incurred before 1 August 2008, Chapter 2 of Part 13 (relief for SMEs: cost of R&D borne by SME) applies with the omission of—
a
section 1052(2)(d),
b
section 1071(3)(d),
c
in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and
d
section 1140, as it applies for the purposes of that Chapter.
2
In relation to expenditure incurred before 1 August 2008, Chapter 3 of Part 13 (relief for SMEs: cost of R&D sub-contracted to SME) applies with the omission of—
a
section 1066(3)(d), and
b
section 1140, as it applies for the purposes of that Chapter.
3
In relation to expenditure incurred before 1 April 2006, Chapter 4 of Part 13 (relief for SMEs: subsidised expenditure on R&D) applies with the omission of—
a
section 1071(3)(d),
b
in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and
c
section 1140, as it applies for the purposes of that Chapter.
4
In relation to expenditure incurred before 1 April 2006, Chapter 5 of Part 13 (relief for large companies) applies with the omission of—
a
section 1077(2)(d), and
b
section 1140, as it applies for the purposes of that Chapter.
5
In relation to expenditure incurred before 1 August 2008, Chapter 7 of Part 13 (relief for SMEs and large companies: vaccine research etc) applies with the omission of—
a
section 1101(4)(d), and
b
section 1140, as it applies for the purposes of that Chapter.